These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 33998)

  • 1. Effect of nadolol in treatment of hypertension.
    Volicer L; Liang CS; Gavras H; Tifft CP; Kershaw GR; Gavras I; Griffith DL; Vukovitch R; Brunner HR
    J Clin Pharmacol; 1979; 19(2-3):137-47. PubMed ID: 33998
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dose-ranging study of the new beta-adrenergic antagonist nadolol in the treatment of essential hypertension.
    Frithz G
    Curr Med Res Opin; 1978; 5(5):383-7. PubMed ID: 26519
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preserved renal perfusion during treatment of essential hypertension with the beta blocker nadolol.
    O'Connor DT; Barg AP; Duchin KL
    J Clin Pharmacol; 1982 Apr; 22(4):187-95. PubMed ID: 6124557
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Renin and beta-blockade: prorenin and aldosterone may explain the controversy.
    McKenna F; Davison AM
    Clin Nephrol; 1986 Mar; 25(3):149-54. PubMed ID: 2869848
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of nadolol beta-blockade on blood pressure in hypertension.
    Duchin KL; Vukovich RA; Dennick LG; Groel JT; Willard DA
    Clin Pharmacol Ther; 1980 Jan; 27(1):57-63. PubMed ID: 6101312
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term renal hemodynamic effects of nadolol in patients with essential hypertension.
    Frohlich ED; Messerli FH; Deslinski GR; Kobrin I
    Am Heart J; 1984 Oct; 108(4 Pt 2):1141-3. PubMed ID: 6148875
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Veterans Administration cooperative study on nadolol as monotherapy and in combination with a diuretic.
    Freis ED
    Am Heart J; 1984 Oct; 108(4 Pt 2):1087-91. PubMed ID: 6148868
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nadolol in essential hypertension: effect on ambulatory blood pressure, renal haemodynamics and cardiac function.
    Dupont AG; Vanderniepen P; Bossuyt AM; Jonckheer MH; Six RO
    Br J Clin Pharmacol; 1985 Aug; 20(2):93-9. PubMed ID: 2864051
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [The renin-aldosterone system in essential hypertension--hypotensive action of beta adrenergic blocking agents and variation of the renin-aldosterone system (author's transl)].
    Hata S
    Nihon Naibunpi Gakkai Zasshi; 1977 Oct; 53(10):1129-39. PubMed ID: 22466
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prorenin and beta-blockade in hypertension.
    McKenna F; Davison AM
    Proc Eur Dial Transplant Assoc; 1983; 20():566-71. PubMed ID: 6140678
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Twenty-four-hour blood pressure profile and blood pressure variability in untreated hypertension and during antihypertensive treatment by once-a-day nadolol.
    Mancia G; Ferrari A; Pomidossi G; Parati G; Bertinieri G; Grassi G; Gregorini L; di Rienzo M; Zanchetti A
    Am Heart J; 1984 Oct; 108(4 Pt 2):1078-83. PubMed ID: 6148866
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Controlled trial on three beta-blockers: antihypertensive efficacy and effect on the hypertensive heart disease.
    Pupita F; Ansuini R; Belogi M; Pupita G; Gaggi S
    Int J Clin Pharmacol Res; 1985; 5(6):439-45. PubMed ID: 2869001
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term experience with nadolol in treatment of hypertension and angina pectoris.
    Alexander JC; Christie MH; Vernam KA; Fand RS; Shafer WB
    Am Heart J; 1984 Oct; 108(4 Pt 2):1136-40. PubMed ID: 6148874
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bucindolol, a beta-adrenoceptor blocker with vasodilatory action: its effect in systemic hypertension.
    Rotmensch HH; Rocci ML; Vlasses PH; Swanson BN; Fedder IL; Soyka L; Ferguson RK
    Am J Cardiol; 1984 Aug; 54(3):353-6. PubMed ID: 6147080
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Evaluation of hypotensive effect of nadolol].
    Cybulska I; Brym E; Czerniewska E; Wołyńczyk-Niegowska J
    Pol Arch Med Wewn; 1980 Dec; 64(6):475-80. PubMed ID: 6111065
    [No Abstract]   [Full Text] [Related]  

  • 16. Long term treatment of moderate hypertension with penbutolol (Hoe 893d). I. Effects on blood pressure, pulse rate, catecholamines in blood and urine, plasma renin activity and urinary aldosterone under basal conditions and following exercise.
    Hansson BG; Hökfelt B
    Eur J Clin Pharmacol; 1975 Oct; 9(1):9-19. PubMed ID: 9298
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Initial experience with a new long-acting beta-blocker, nadolol, in hypertensive patients.
    Hitzenberger G
    J Int Med Res; 1979; 7(1):33-8. PubMed ID: 33862
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nadolol and propranolol in the treatment of hypertension: a double-blind comparison.
    El Mehairy MM; Shaker A; Ramadan M; Hamza S; Tadros SS
    J Int Med Res; 1980; 8(3):193-8. PubMed ID: 6104614
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Field trial with a new betablocker (Solgol)].
    Piergies A; Schimert G
    MMW Munch Med Wochenschr; 1980 Oct; 122(42):1473-6. PubMed ID: 6110182
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Initial therapy of essential hypertension: diuretic or beta blocker?
    Finnerty FA
    J Fam Pract; 1980 Aug; 11(2):199-205. PubMed ID: 6106039
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.